TITLE

Castrate-resistant prostate cancer

AUTHOR(S)
Black, Peter
PUB. DATE
August 2011
SOURCE
Oncology Exchange;Aug2011, Vol. 10 Issue 3, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the development of various treatments for castrate-resistant prostate cancer (CPRC). It reviews some of the treatments in treating patients with CPRC which include abiratorine, denosumab, and zoledronic acid. It highlights various breakthroughs in managing CPRC that included novel treatment paradigms such as vaccine therapy and novel agents
ACCESSION #
66173880

 

Related Articles

  • Unique Treatment Raises Tricky Bioethical Issues. Yard, Delicia Honen // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p28 

    The article discusses tricky bioethical issues related to the treatment of prostate cancer. It mentions that despite the benefits of vaccine for advanced castration-resistant prostate cancer, the treatment is an extremely high cost. It tackles the bioethical issue of the Provenge, a treatment...

  • Sipuleucel-T Suspension for Intravenous Infusion (Provenge). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85 

    The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.

  • Other Cancers News Headlines May 15, 2003--June 14, 2003.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p34 

    Presents an update on drug development for various cancers, compiled as of June 14, 2004. Data suggesting the efficacy of Trisenox in multiple myeloma treatment; Cell Genesys' achievement of positive results with GVAX cancer vaccine in myeloma and prostate cancer; Revimid data showing its...

  • Androgen Deprivation Therapy for Localized Prostate Cancer. Kuritzky, Louis // Internal Medicine Alert;8/29/2008, Vol. 30 Issue 16, p128 

    The article reports on the androgen deprivation therapy (ADT) for localized prostate cancer (P-CA), the most common cancer among American men.

  • Notebook.  // FDA Consumer;Nov/Dec97, Vol. 31 Issue 7, p37 

    States that the combination of two prostate cancer therapies can improve the chances of survival. Survival rate using the therapies.

  • First cancer vaccine approved for use in people.  // New Scientist;5/8/2010, Vol. 206 Issue 2759, p5 

    The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.

  • KEY DEVELOPMENTS PROSTATE CANCER.  // Update;9/24/2004, Vol. 69 Issue 4, p108 

    This article presents information on methods for treating and preventing prostate cancer. Studies suggest dietary prevention, including supplements such as vitamin E and selenium and tomato-based foods, may be protective. A trial is being conducted on high intensity focused ultrasound in the...

  • Cabazitaxel.  // Australian Prescriber;Aug2012, Vol. 35 Issue 4, p129 

    The article offers information on the drug cabazitaxe that is indicated for treatment of metastatic prostate cancer. It states that cabazitaxel is derived from the needles of European yew tree, which has an antitumour activity on cells that are poorly responsive to docetaxel. It discusses the...

  • Drugs in Clinical Development for Prostate Cancer.  // Pharmaceutical Medicine - New Zealand;2011, Vol. 25 Issue 6, p387 

    The article offers information on the drugs that are in clinical development for prostate cancer. The treatment options available for patients with prostate cancer are discussed. Also mentioned are the risks associated with estrogen therapy and luteinizing hormone-releasing hormone (LHRH)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics